INTRODUCTION
Four mechanisms have been identified whereby contractile agonists can induce vascular smooth-muscle contraction : (i) depolarization of the sarcolemma, which activates voltage-gated Ca# + channels and entry of extracellular Ca# + into the sarcoplasm, (ii) activation of Ca# + -permeable channels (including L-type Ca# + channels) without a change in membrane potential, (iii) release of Ca# + from the sarcoplasmic reticulum into the sarcoplasm, and (iv) increased Ca# + sensitivity of contraction [1] . The first three mechanisms all involve an increase in sarcoplasmic free [Ca# + ]. As a result, calmodulin (CaM) becomes saturated with Ca# + (four Ca# + ions bind per CaM molecule) and undergoes a conformational change with exposure of hydrophobic sites of interaction with the target enzyme myosin light-chain kinase (MLCK) [2, 3] . The interaction of Ca# + % \CaM with MLCK activates the kinase that catalyses transfer of the terminal phosphoryl group of MgATP# − to serine-19 of the two 20 kDa light chains of myosin (LC #! ). This simple phosphorylation reaction triggers cycling of myosin cross-bridges along actin filaments and forces development or shortening of the muscle. Myosin phosphorylation is necessary and sufficient for contraction of smooth muscle in general. However, several instances have been reported of dissociation of myosin phosphorylation and force, e.g. [4] [5] [6] [7] [8] [9] .
In this study, we have investigated the mechanism whereby an α " -adrenoceptor agonist induces contraction of de-endothelialized rat-tail arterial smooth muscle, in particular the relationship between LC #! phosphorylation and contraction.
Abbreviations used : CaM, calmodulin ; H-T, Hepes/Tyrode ; LC 20 , 20 kDa light chain of smooth-muscle myosin ; ML-9, 1-(5-chloronaphthalene-1-sulphonyl)homopiperazine ; MLCK, myosin light-chain kinase. 1 Present address : Department of Pharmacology, Meiji College of Pharmacy, 1-35-23 Nozawa, Setagayu-ku, Tokyo 154, Japan. 2 To whom correspondence should be addressed.
amino acid analysis revealed that LC #! phosphorylation occurred exclusively at serine-19. The sustained phase of contraction was eliminated by removal of extracellular Ca# + and the phasic response was eliminated by depletion of endogenous Ca# + stores. Both phases of the contractile response were restored by readdition of Ca# + to the bathing medium. LC #! phosphorylation and both phases of the contractile response to 0.3 µM cirazoline were inhibited by the myosin light-chain kinase inhibitor ML-9 (30 µM). Resting LC #! phosphorylation, however, was unaffected by ML-9. Finally, both phasic and tonic responses to 0.3 µM cirazoline were partially inhibited by chloroethylclonidine (50 µM), suggesting the involvement of both α "A and α "B adrenoceptors in these contractile responses.
MATERIALS AND METHODS

Materials
[$#P]P i (10 mCi\ml) and [γ-$#P]ATP ( 5000 Ci\mmol) were purchased from Amersham (Oakville, Ontario, Canada). 1-(5-Chloronaphthalene-1-sulphonyl)homopiperazine (ML-9) hydrochloride was purchased from Calbiochem (Windsor, Ontario, Canada), chloroethylclonidine dihydrochloride from ICN Biomedicals (Aurora, OH, U.S.A.) and okadaic acid from Upstate Biotechnology (Lake Placid, NY, U.S.A.). The following proteins were purified as described previously : CaM [10] , MLCK [11] and LC #! [12] .
Preparation of muscle strips and tension measurement
The endothelial layer and adventitial tissue were removed mechanically from tail arteries of male Sprague-Dawley rats (250-350 g). Helical strips [0.5 mmi(6-7) mm] were cut and stored in Hepes\Tyrode (H-T) solution (137 mM NaCl\2.7 mM KCl\ 1.8 mM CaCl # \1 mM MgCl # \5.6 mM glucose\10 mM Hepes, pH 7.4). Muscle strips were mounted horizontally between two hooks and immersed in a pool of solution (0.8 ml), which was rounded by surface tension on a rotation plate of 6 cm diameter. One hook was connected to a force\displacement transducer mounted on a micromanipulator and the other to a second micromanipulator. Solution changes were effected rapidly by rotation of the plate. A resting tension of 75 mg was experimentally determined to give a maximal contractile response to 40 mM KCl and was used for all experiments. Once mounted, muscle strips were held at this resting tension in H-T solution at room temperature (20 mC) for 45 min before transfer to the test solutions indicated in the text. Sequential treatments with cirazoline separated by periods of relaxation elicited identical contractile responses in the same muscle strip. All solutions were bubbled thoroughly with 100 % O # .
Quantification of myosin light-chain phosphorylation
Tissue samples were frozen at selected times following agonist stimulation in 10 % (w\v) trichloroacetic acid\20 mM dithiothreitol in dry ice\acetone for 10 min and kept at k80 mC for 1 h. Frozen muscle strips were then washed with 10 mM dithiothreitol in acetone at room temperature. The tissues were freeze-dried for 2 h and homogenized in extraction buffer (6 M deionized urea\ 20.1 mM Tris\22.2 mM glycine\10 mM dithiothreitol\10 mM EGTA\1 mM EDTA\1 mM PMSF\0.6 M KI\0.15 mM Bromophenol Blue) for 90 min. After filtration and centrifugation, phosphorylated and unphosphorylated LC #! were separated by urea\glycerol gel electrophoresis [13] and transblotted to nitrocellulose membrane (0.2 µm ; Bio-Rad, Mississauga, Ontario, Canada) in 10 mM sodium cyclohexylaminopropanesulphonic acid, pH 11, in a mini transblot cell (Bio-Rad) at 27 V and 5 mC for 16 h. LC #! was detected using a polyclonal antibody raised in rabbits against purified chicken gizzard LC #! . The antibody was purified from antiserum using HiTrap Protein A (Pharmacia, Baie d'Urfe, Que! bec, Canada) and was used at a dilution of 1 : 1000 with the Boehringer-Mannheim Chemiluminescence Western Blotting Kit, as described by the manufacturer. Phosphorylated and unphosphorylated LC #! bands were quantified by densitometric scanning using a Pharmacia Image Master Desktop Scanning System.
Radiolabelling of muscle strips
De-endothelialized rat-tail arterial muscle strips were incubated for 16 h at room temperature (20 mC) in 10 ml of carrier-free [$#P]orthophosphate (0.1 mCi\ml) in H-T solution. Excess radiolabel was removed by washing 3 times in H-T solution. Force was recorded and muscle strips processed for urea\glycerol gel electrophoresis as described above. Phosphorylated LC #! was detected by autoradiography and was cut out of the gel for phosphopeptide mapping and phosphoamino acid analysis.
Phosphopeptide mapping and phosphoamino acid analysis
LC
#! in the gel slices was digested with trypsin and the peptides were separated by two-dimensional thin-layer electrophoresis\ chromatography as described by Colburn et al. [14] . Phosphopeptides were detected by autoradiography and this region of the plate was scraped off. The phosphopeptide was extracted and subjected to acid hydrolysis and two-dimensional phosphoamino acid analysis using the method of Cooper et al. [15] , as described by Colburn et al. [14] , except that hydrolysis was effected in 250 µl of 6 M HCl at 110 mC for 2 h, and first-dimension electrophoresis was carried out for 80 min and second-dimension electrophoresis for 70 min.
Phosphorylation of LC 20 in vitro
Purified chicken-gizzard LC #! (0.1 mg\ml) was phosphorylated at serine-19 by incubation for 5 min at 30 mC in 25 mM Tris\HCl (pH 7.5)\60 mM KCl\0.
ATP (490 c.p.m.\pmol) with CaM (10 µg\ml) and MLCK (10 µg\ml). Phosphorylated LC #! was purified by SDS\PAGE [16] before tryptic digestion and phosphopeptide mapping as described above.
RESULTS
Helical strips of endothelium-free rat-tail arterial smooth muscle contracted in response to cirazoline (an α " -adrenoceptor agonist ; see the Discussion section) in a concentration-dependent manner, with an EC &! of 0.23 µM (results not shown). The contractile response to a submaximal concentration (0.3 µM) of cirazoline was biphasic ( Figure 1 ) : an initial phasic contraction, which peaked 30 s after the addition of cirazoline, was followed by a sustained tonic contraction that reached a plateau 5 min after the addition of agonist. LC #! phosphorylation levels were quantified by Western blotting of urea\glycerol gels with enhanced chemiluminescence detection, as described in the Materials and methods section (Figure 1 ). LC #! phosphorylation levels, like contraction, increased rapidly in response to cirazoline from a 20 by urea/glycerol gel electrophoresis. This method was used to obtain the quantitative data shown in Figures 1 and 9 . α 1 -Adrenoceptor-mediated myosin phosphorylation Figure 3 Phosphopeptide mapping of LC 20 , phosphorylated in response to cirazoline LC 20 bands (see Figure 2A) were cut out of the gel, the light chain was digested with trypsin and the tryptic peptides were separated by two-dimensional thin-layer electrophoresis/chromatography (TLE, TLC) as described in the Materials and methods section. resting level of 0.22p0.06 mol of P i \mol of LC #! to a peak of 0.54p0.05 mol of P i \mol of LC #! 15 s after agonist addition. LC #! phosphorylation then declined slightly before increasing again to a sustained level of 0.58p0.08 mol of P i \mol of LC #! . The biphasic contraction followed very closely the change in myosin phosphorylation. The biphasic nature of myosin phosphorylation was confirmed by urea\glycerol gel electrophoresis and autoradiography of tissue strips pre-equilibrated with [$#P]orthophosphate and stimulated with cirazoline. Results of a representative experiment are shown in Figure 2(A) . Western blotting following separation of unphosphorylated and phosphorylated LC #! enabled determination of the phosphorylation stoichiometry ( Figure 2B ).
Phosphopeptide mapping and phosphoamino acid analysis indicated that all the phosphate incorporation was into serine- 19. A single tryptic phosphopeptide was detected in resting muscle and at 15 s, 1 min and 5 min following addition of cirazoline ( Figures 3A-3D ). This phosphopeptide contained only phosphoserine ( Figure 4) and it co-migrated with the tryptic phosphopeptide obtained from muscle strips contracted with 40 mM K + ( Figure 3G ). The latter phosphopeptide also comigrated with the tryptic phosphopeptide derived from purified chicken-gizzard LC #! phosphorylated in itro by MLCK, which is known to occur at serine-19 ( Figures 3E and 3F ). Figure 5 confirms the exclusive phosphorylation of serine-19 in muscle strips stimulated with 40 mM KCl. Phosphoamino acid analysis Figure 5 Phosphopeptide mapping of LC 20 , phosphorylated in response to
The experimental protocol was as described in the legend to Figure 3 indicated that the tryptic phosphopeptide in each case contained phosphoserine but not phosphothreonine or phosphotyrosine (results not shown).
To determine the relative importance of extracellular versus intracellular Ca# + stores in the two phases of the cirazolineinduced contraction, control contractions were compared with contractions elicited in muscle strips treated (i) with Ca# + -free solution containing 2 mM EGTA for 5 min, (ii) continued incubation in Ca# + -free solution containing 2 mM EGTA for 60 min, and (iii) with Ca# + -free solution containing 2 mM EGTA for another 5 min, followed by Ca# + -containing solution for 60 min. Brief treatment to remove extracellular Ca# + resulted in loss of the sustained contractile response to cirazoline without affecting the phasic response ( Figure 6 ). When intracellular Ca# + stores were depleted by repeated treatment with cirazoline in the absence of Ca# + , the contractile response to cirazoline was almost completely abolished. The biphasic contraction was restored following refilling of intracellular Ca# + stores and provision of extracellular Ca# + . Figure 7 confirms that the phasic contraction remaining in the absence of extracellular Ca# + is due to release of Ca# + from the sarcoplasmic reticulum. Thus following a 5-min incubation in Ca# + -free solution, caffeine elicited a normal phasic contraction but failed to do so after continued incubation in Ca# + -free solution.
The MLCK-selective membrane-permeant inhibitor ML-9 (30 µM) almost completely abolished both phases of the contractile response to cirazoline ( Figure 8A ). Only a very small component of the phasic response was retained in the presence of ML-9 ( Figure 8B ). Figure 9 indicates that ML-9 completely prevented the increase in LC #! phosphorylation due to cirazoline. Interestingly, ML-9 did not reduce the resting level of LC #! phosphorylation.
Finally, the involvement of α " -adrenoceptor subtypes in the cirazoline-induced contraction was investigated using chloroethylclonidine, an irreversible inhibitor of α "B and α "D adrenoceptors that is without effect on α "A adrenoceptors [17, 18] . Figure  10 shows that both the phasic and tonic components of the cirazoline-induced contraction were partially inhibited by chloroethylclonidine, the phasic component by 36.1p2.9 % and the tonic component by 43.6p6.7 % (P 0.01 in each case). 
DISCUSSION
Three pharmacological tools were used in this study of α " -adrenoceptor-mediated activation of LC #! phosphorylation and contraction of rat-tail arterial smooth muscle : the α " -adrenoceptor agonist cirazoline, the MLCK inhibitor ML-9 and the α "B -and α "D -adrenoceptor antagonist chloroethylclonidine. There is strong evidence in the literature that cirazoline behaves as an α " -adrenoceptor agonist when applied to rat-tail arterial smooth muscle. Thus Li and Triggle [19] showed that the contractile responses of rat-tail arterial rings to cirazoline are sensitive to prazosin at concentrations appropriate for an α " -adrenoceptor-mediated response. Furthermore, Li et al. [20] reported that treatment of isolated, single, rat-tail arterial smooth-muscle cells with prazosin greatly depressed responses to cirazoline. Finally, we have shown that prazosin also inhibits cirazoline-induced contraction of rat-tail arterial-muscle helical strips (L. Weber and M. P. Walsh, unpublished result).
ML-9 has been reported to be a selective inhibitor of MLCK [21] and was shown to inhibit the KCl-stimulated increase in LC #! phosphorylation and force development in rabbit mesenteric artery [22, 23] . This inhibition by ML-9 was not affected by treatment with adrenergic or cholinergic antagonists. Moreover, ML-9 exhibited non-competitive inhibition with noradrenaline (norepinephrine)-, 5-hydroxytryptamine-, angiotensin II-, histamine-and CaCl # -induced contractions, suggesting that the mechanism of action of ML-9 does not involve blocking of a membrane receptor. In all cases, inhibition of contraction by ML-9 could be explained by its ability to inhibit MLCK-catalysed phosphorylation of LC #! . Three α " -adrenoceptor subtypes have been identified : α "A , α "B and α "D [18] . The α "A -adrenoceptor is resistant to covalent modification and inactivation by chloroethylclonidine, whereas α "B -and α "D -adrenoceptors are alkylated and inactivated by chloroethylclonidine. Although mRNA for the α "D -adrenoceptor has been detected in the rat-tail artery (and all other arteries examined) [24] , this subtype does not appear to play a role in mediating contractile responses in rat-tail, mesenteric and renal arteries, but does appear to play a role in rat aorta and iliac artery [25] .
The following principal conclusions are reached from this study. (i) The contractile response to a submaximal concentration of cirazoline is biphasic, consisting of a rapid phasic contraction followed by a sustained tonic contraction. (ii) The time course of LC #! phosphorylation, which occurs exclusively at serine-19, closely parallels that of force. (iii) The phasic component of the contraction is due to the release of Ca# + from the sarcoplasmic reticulum and the tonic component to the entry of extracellular Ca# + . (iv) Both phases of the contraction and LC #! phosphorylation are abolished by pre-treatment with the membranepermeant MLCK inhibitor ML-9. (v) Resting LC #! phosphorylation levels (approx. 0.2 mol of P i \mol of LC #! ) are unaffected by ML-9. (vi) α "A and α "B adrenoceptors are involved in both the phasic and tonic components of cirazoline-induced contraction. These results support a mechanism whereby α " -adrenoceptor agonist stimulation triggers both Ca# + release from the sarcoplasmic reticulum and Ca# + entry from the extracellular space, leading to LC #! phosphorylation specifically at serine-19 and force development. Force maintenance also correlates with high levels of LC #! phosphorylation. In this tissue, under the conditions described, we detected no latch state, i.e. reduction of LC #! phosphorylation during force maintenance [26] . Higher concentrations of cirazoline (10 µM), however, triggered a monophasic contractile response with a transient increase in LC #! phosphorylation, i.e. force was maintained following a decline in LC #! phosphorylation to resting levels (results not shown).
Using a different α " -adrenoceptor agonist, phenylephrine, Chen and Rembold [27] concluded that a low concentration of the agonist (0.1 µM) induced contraction of rat-tail arterial smooth-muscle rings primarily via depolarization of the sarcolemma with entry of extracellular Ca# + via voltage-gated Ca# + channels, and via increased Ca# + sensitivity, with a minor contribution due to entry of extracellular Ca# + , independently of changes in membrane potential (principally via L-type Ca# + channels). Release of Ca# + from intracellular stores was only observed at high concentrations of phenylephrine (10-100 µM). The situation with cirazoline-induced contraction is clearly quite different since a submaximal concentration elicited a rapid phasic contraction due entirely to the release of intracellular stored Ca# + , and a sustained contraction due to the entry of extracellular Ca# + . It has been postulated that α "A adrenoceptors act via Ca# + influx and α "B adrenoceptors via intracellular Ca# + release [28, 29] . However, partial overlap between the signal-transduction mechanisms of these two α " -adrenoceptor subtypes has been indicated [30] [31] [32] . Our results with chloroethylclonidine would support such overlap. Under the conditions used in this study there is a clear temporal distinction between intracellular Ca# + release and extracellular Ca# + entry. A plausible explanation would be that the submaximal concentration of cirazoline first of all triggers Gprotein-mediated activation of phosphatidylinositol-specific phospholipase C via α "A -and α "B -adrenoceptors, resulting in Ins(1,4,5)P $ production, release of Ca# + from the sarcoplasmic reticulum and rapid contraction due to LC #! phosphorylation at serine-19. The increase in [Ca# + ] i could then increase Cl − channel activity [33] , resulting in depolarization of the sarcolemma and Ca# + influx via voltage-gated Ca# + channels. Since 1,2-diacylglycerol is also generated by phosphatidylinositol-specific phospholipase C, protein kinase C may be involved in the mechanism of activation of Ca# + entry.
Finally, the observation that the resting level of LC #! (serine- 19) phosphorylation is unaffected by ML-9 suggests that this phosphorylation is not catalysed by Ca# + \CaM-activated MLCK. Possibilities include MLCK autophosphorylated at threonine-803 (which exhibits Ca# + \CaM-independent activity) [34] , Rho-associated kinase [35] , Ca# + \CaM-dependent protein kinase II (an autophosphorylated form exhibits Ca# + \CaM-independent activity) [36] or mitogen-activated-protein-kinaseactivated protein kinase-2 [37] . Further studies will be required to identify the kinase involved.
